US EditionPublished • loading... • Updated
Nona Biosciences Appoints Dr. Hongjiang Miao as Chief AI Officer to Advance A³ Strategy and AI-Driven Drug Discovery
- Nona Biosciences has appointed Dr. Hongjiang Miao as Chief AI Officer to lead its A3 strategy for AI-driven drug discovery.
- Dr. Miao will work with all departments to integrate AI technologies with Nona's biological platforms.
- Nona Biosciences aims to provide comprehensive solutions for biological drug discovery and development.
- The company aims to advance drug invention through technologies like Harbour Mice® and end-to-end preclinical services.
Insights by Ground AI
46 Articles
46 Articles
The Berkshire Eagle+45 Reposted by 45 other sources
Nona Biosciences Appoints Dr. Hongjiang Miao as Chief AI Officer to Advance A³ Strategy and AI-Driven Drug Discovery
CAMBRIDGE, Mass., Dec. 3, 2025 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a global biotechnology company providing integrated solutions for biological drug discovery and development from I to I® (Idea to IND), today announced the appointment of Dr. Hongjiang…
Coverage Details
Total News Sources46
Leaning Left5Leaning Right7Center14Last UpdatedBias Distribution54% Center
Bias Distribution
- 54% of the sources are Center
54% Center
L 19%
C 54%
R 27%
Factuality
To view factuality data please Upgrade to Premium
